Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
That's correct Steve ,the Mygo mini and Mygo Pro are the original names of the two devices. When you see the accounts for It-Is International they show 5.9 million of inter company sales to Novacyt and over 1 million of other sales .The latter will more than likely be Mygo devices that they still sell.
The Mygo device is the Q16 as far as I'm aware. Novacyt I believe just stuck their name on it as an OEM deal with IT-IS, which is why the purchase of the company was a great move now
DRB, that link you posted is what started me looking in the first place .If you look on the Tib-Molbiol website their covid variant tests can be used on the Mygo devices which It-Is International manufacture.
Have written to Mandy about all of this earlier and she has acknowledged my mail and will forward to relevant internal area. They may already be aware , it is not something I would exoect Mandy to be aware of. K
Noone is fully registered yet.
Theyre both waiting for examination.
Molbiol started one month earlier, but theyre At the same stage.
Our lawyer for trademark applications is based in the US, theirs is in Germany. Maybe that Can help getting things more rapidly...
Exmex, I found this with a date of May 4 2021. Have you seen it?
https://alter.com/trademarks/winterplex-79315083
Agree something seems amiss EXMEX.
Suggest sending these concerns to Nick Plummer, General Counsel and Company Secretary at Novacyt Group
Nick.Plummer@
Don’t we have our own in-house barrister type on the BOD,S, go get him Flloyd and make my day.
Good spot exmex. At first look, thought it might have been our product as part of a partnership. Roche are taking over Tib. If it is a partnership then this could be the big news mentioned in the video about one big market in the EU. I always had Germany down for that market.
If not, the ncyt need to know about this so we can shoot them out of the sky.
More than likely our Winterplex branded under Molbiol....
Complete OEM solutions
We can project manage the entire OEM process for your organisation. This entails complete, seamless integration of your branding in to our operations workflow to ensure your products are packaged and specified in the format you prefer.
White label or full branded solutions
We can supply goods in bulk under white label for your own repackaging systems. Alternatively we can create new packaging solutions to your specification complete with your own branding. Or if you prefer we can pack directly in to your own packaging solution. Product handbooks and protocols can be rebranded alongside packaging too.
Good spot; the TM application is for the same class(es) so really odd. Probably a good idea to let Mandy know.
Do Novacyt know that there is a German company using the Winterplex name on their version of a covid 19 ,fluA ,fluB and rsv test? A search of trademark applications in the UK shows that Novacyt first filed to trademark the name Winterplex on 21/01/21 and it was eventually registered and approved on 11/06/21.The german company Tib-Molbiol filed with the UK patent office with a product of the same name in May and it seems that the test is already internationally registered. Currently the German test has been published in the UK trademark journal on 24/09/21 .There are 60 days from that date for objections to the use of the name Winterplex to be put forward .If there are no objections during that period the test then goes on to be registered. Very strange how another company has used exactly the same trademark all in capital letters,
https://www.tib-molbiol.de/company
https://www.tib-molbiol.de/covid-19
https://trademarks.ipo.gov.uk/ipo-tmtext/page/Results
Could posters please refrain from making finger in the air cash at bank estimates in future, simply because it seems likely Novacyt income from assay sales and instruments must be increasing in line with other companies statements of being very busy lately.
The cost of setting up Novacyt US Inc cannot possibly be established because insufficient info concerning these costs is available in the public domain.
However, I accept we are totally committed to setting the company up after Raimondo's statement :
"The focus for us going forward is to establish ourselves in the America's especially the US, and also to expand our global footprint, focusing on one of the key European markets."
I'll raise a glass tonight to Kevin and Raimondo's efforts to get this business set up on a strong footing, such that we can see some action soon.
@Kitzie
Hope you are right regards the U.S.A. and S.A.
However, why did that big roll of ' Fragile ' labels take centre stage at the relevant point in the video.
Not very subliminal - what was that all about ?
some excellent comments made above...IMO, GM looks knackered.....for me hands down the near to patient testing in 10 mins will solve all our problems for large venue testing...there's a lot of coughing and spluttering going on and no one knows what they have.....and the icing on the cake is the talk about investment going into the USA and South America.....the yanks are keen to uptake European/ UK products very readily....seen it many a time in pharma....one sniff of success and NCYT will be bought in a flash !
The comments in the video about bringing the processing time of a test down from 60 minutes to 10 minutes reminded me of this report from Birmingham University in August. They have developed a test which can show results in under 10 minutes and can be used on standard lab equipment.At the end of the article they mention that they are seeking partner's to bring the test to market .
Could Novacyt be working on a similar concept?
https://www.birmingham.ac.uk/news/latest/2021/08/birmingham-researchers-confirm-speed-simplicity-and-sensitivity-for-new-covid-19-test.aspx
@poidster I love reading your posts and agree wholeheartedly with your comments. Many on here are already stretched and over invested. Whilst I am behind Novacyt 100% I would urge you to move forward with caution. The anxiety and stress this depressed share price can cause is seen first hand on this board. I wish you well whatever you decide.
@Poidster
Agree - so innovatiive and outstanding in their field yet difficult decisions to be made on a personal level regards investment. Maybe it's down to whether you have a better head or a better heart and sometimes it takes longer for the heart to catch up.
Regards marketing and improving sales, I think we are all able to play a small part in shouting this companies merits from the rooftops intead of continually moaning about our own personal circumstances on a daily basis.
Liked the video which exhibited an exuberant mix of youth, experience and ethnicity while focusing on the task in hand with great expectations and hope for the future. My main criticism would be around some areas which made some of the production methods look a bit like a cottage industry - which on reflection, given the situation in certain places, may be no bad thing.
Poidster -
I would say don't make further decisions until after the AGM, and - if quorate - the EGM.
I expect further discussion of the subjects within the video at this meeting.
a) A new CEO should have something to say on future priorities, - possibly Marketing and sales.
b) Material that amplifies the video could be discussed.
The presentation backs up what appears in the 22.06.2021 RNS Novacyt-full-year-2020-results 'Strategy Update', so I'm thinking AD might further amplify at AGM.
Bullet points found within the Strategy Update:
• Investment in R&D to deliver new products in the respiratory and transplant
bacterial and viral diagnostic markets
• Investment in commercial infrastructure to establish a direct sales force in key
markets in Europe and the US
• Selective product/technology and company acquisitions to generate additional
revenues and expand its core capabilities whilst maintaining attractive margins
• Investment in developing new IP portfolio to enhance and secure future value
As you say sp in the bin, but not for much longer if M&A activity arrives.
The video contains this statement of intent that will wake up the competition:
"Guillermo Raimondo (3:06)
The focus for us going forward is to establish ourselves in the America's especially the US, and also to expand our global footprint, focusing on one of the key European markets."
IMO I expect US based competitors to allow us to invest in Novacyt US Inc as we have stated, then make any offer only when it becomes clear our global and/or US market share is increasing markedly.
If little increase in market share, then any predator offer might be because they covet our instrumentation, R&D, and Bioinformatics teams, to say nothing of the catalogue of Primer design assays and Microgen LFT's etc.
Novacyt cannot be ignored by competitors because the speed with which we innovate is a clear and present danger to competitor profits, if not now, then very possibly soon. The term 'market disruptive', applies to many of our products such as Q16/Q32, PROmate, SNP-sig assays, Escapeplex et al. They need more marketing spend to wake the market up to Navacyt's potential, and that will happen now DA has arrived.
Excellent video. Thanks for sharing
Impressive stuff, they wouldn't have mentioned the 10 min PCR if it wasn't something they think they can't deliver.
This is what frustrates the hell out of me. They are honestly outstanding in their field, way ahead of everyone else, agile, nimble and consistently ahead of the game, all the major players are running to catch up but novacyt makes them look like they are standing still.
It's almost as if they are embarrassed by their development, the SP is in the bin. I just don't get it.
Other AIM companies would be shouting this from the rooftops.
I've given up trying to work this out, none of it makes any sense anymore.
Currently considering going sh1 t or bust and trying to average down but honestly I have no clue as to whats going to happen, my head says this is a massive opportunity but my heart is saying, don't lose anymore
# me too they are who I'd love to see get a bonus.
Thats the standout to me , reckon they are on it already. Please tell me that gets you going Dunc :)
10 min PCR test = mid cap
Simple equation
Hmmm. a ten minute PCR test, now that would be something.